Mar 5, 2018 · Kaplan–Meier analysis indicated that HCC patients with high expression of CDK7 exhibited worse overall survival as compared to patients with low expression of CDK7 (n = 80, P = 0.048, log-rank...

Our studies indicate that targeting gene transcription by CDK7 inhibition could be a new effective strategy against HCC, in which MYC plays crucial roles in tumor initiation and progression.

Conclusions: The CDK7 expression level in HCC is associated with HCC progression, prognosis and the cell proliferation capacity. CDK7 may act as a potential target for HCC, and THZ1 might be a potent medicine for HCC treatment.

Our study suggested that BRD4 and CDK7 coupled can be a valuable biomarker in HCC diagnosis and the combination of JQ1 and THZ1 can be a promising therapeutic treatment against HCC.

Mar 28, 2022 · Here, we show that three HCC lines, HepG2, Hep3B, and SK-Hep-1, were highly susceptible to the CDK7 inhibitor THZ1. In mouse models, THZ1 effectively reduced HepG2 tumor growth and tumor weight. THZ1 arrested cell cycle and …

Sep 15, 2018 · Mechanistically, CDK7 interacted with beta-catenin, enhanced the interaction between beta-catenin and TCF4, and activated beta-catenin/TCF signaling. Taken together, this study demonstrated the oncogenic roles of CDK7 in HCC and suggested that CDK7 might be a promising therapeutic target.

Sep 15, 2018 · Mechanistically, CDK7 interacted with beta-catenin, enhanced the interaction between beta-catenin and TCF4, and activated beta-catenin/TCF signaling. Taken together, this study demonstrated the oncogenic roles of CDK7 in HCC and suggested that CDK7 might be a promising therapeutic target.

Mar 5, 2018 · Two previous studies have shown that MYC proteins are potential biomarkers of response to CDK7 inhibitors in small cell lung cancer and neuroblastoma. 8, 9 Our work now identifies CDK7 inhibition as vulnerability of HCC tumors having high MYC expression.

Jan 9, 2024 · Our study suggested that BRD4 and CDK7 coupled can be a valuable biomarker in HCC diagnosis and the combination of JQ1 and THZ1 can be a promising therapeutic treatment against HCC.

Jan 30, 2024 · Our study suggested that BRD4 and CDK7 coupled can be a valuable biomarker in HCC diagnosis and the combination of JQ1 and THZ1 can be a promising therapeutic treatment against HCC.